Literature DB >> 24634231

Genetic variations of ISL1 associated with human congenital heart disease in Chinese Han people.

Z L Luo1, H Sun2, Z Q Yang2, Y H Ma3, Y Gu1, Y Q He2, D Wei4, L B Xia4, B H Yang1, T Guo5.   

Abstract

Congenital heart disease (CHD) is the most common birth abnormality, but the etiology of CHD is unknown. ISL1 may play a fundamental role in cardiac morphogenesis, and mutations of this gene could cause CHD. To evaluate whether genetic variations of ISL1 are associated with CHD in Chinese Han people, polymerase chain reaction restriction fragment-length polymorphism and SNaPshot were used to examine 9 polymorphisms of ISL1 in 233 patients with CHD as well as 288 healthy controls. We found that one SNP (rs1017) in ISL1 was significantly associated with simple CHD. Genetic variation of ISL1 was confirmed to be associated with the risk of CHD. ISL1 is related to the atrial septal defect group and the ventricular septal defect group, and the genotypes were associated with the occurrence of CHD in the dominant mode of inheritance. We concluded that rs1017 contributed to the risk of CHD in Chinese Han people, and ISL1 may be involved in the formation and development of the heart.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24634231     DOI: 10.4238/2014.February.28.5

Source DB:  PubMed          Journal:  Genet Mol Res        ISSN: 1676-5680


  9 in total

1.  ISL1 loss-of-function mutation contributes to congenital heart defects.

Authors:  Lan Ma; Juan Wang; Li Li; Qi Qiao; Ruo-Min Di; Xiu-Mei Li; Ying-Jia Xu; Min Zhang; Ruo-Gu Li; Xing-Biao Qiu; Xun Li; Yi-Qing Yang
Journal:  Heart Vessels       Date:  2018-11-02       Impact factor: 2.037

2.  Cardiac stem cells: translation to human studies.

Authors:  Zijun Ge; Sean Lal; Thi Y L Le; Cris Dos Remedios; James J H Chong
Journal:  Biophys Rev       Date:  2014-12-03

3.  WDR62 variants contribute to congenital heart disease by inhibiting cardiomyocyte proliferation.

Authors:  Lili Hao; Jing Ma; Feizhen Wu; Xiaojing Ma; Maoxiang Qian; Wei Sheng; Tizhen Yan; Ning Tang; Xin Jiang; Bowen Zhang; Deyong Xiao; Yanyan Qian; Jin Zhang; Nan Jiang; Wenhao Zhou; Weicheng Chen; Duan Ma; Guoying Huang
Journal:  Clin Transl Med       Date:  2022-07

4.  ISL-1 is overexpressed in non-Hodgkin lymphoma and promotes lymphoma cell proliferation by forming a p-STAT3/p-c-Jun/ISL-1 complex.

Authors:  Qiao Zhang; Zhe Yang; Zhuqing Jia; Cuiling Liu; Chen Guo; Huafei Lu; Ping Chen; Kangtao Ma; Weiping Wang; Chunyan Zhou
Journal:  Mol Cancer       Date:  2014-07-29       Impact factor: 27.401

5.  A Novel Role for CSRP1 in a Lebanese Family with Congenital Cardiac Defects.

Authors:  Amina Kamar; Akl C Fahed; Kamel Shibbani; Nehme El-Hachem; Salim Bou-Slaiman; Mariam Arabi; Mazen Kurban; Jonathan G Seidman; Christine E Seidman; Rachid Haidar; Elias Baydoun; Georges Nemer; Fadi Bitar
Journal:  Front Genet       Date:  2017-12-18       Impact factor: 4.599

6.  First report of polymorphisms in MTRR, GATA4, VEGF, and ISL1 genes in Pakistani children with isolated ventricular septal defects (VSD).

Authors:  Sumbal Sarwar; Farah Ehsan; Amna Tahir; Mahrukh Jamil; Saleem Ullah Shahid; Asim Khan; Shahida Hasnain
Journal:  Ital J Pediatr       Date:  2021-03-23       Impact factor: 2.638

Review 7.  Spotlight on Isl1: A Key Player in Cardiovascular Development and Diseases.

Authors:  Jie Ren; Danxiu Miao; Yanshu Li; Rui Gao
Journal:  Front Cell Dev Biol       Date:  2021-11-25

8.  Study of variants associated with ventricular septal defects (VSDs) highlights the unique genetic structure of the Pakistani population.

Authors:  Sumbal Sarwar; Amna Tahir; Zainab Liaqat; Saher Naseer; Rani Summeya Seme; Sabahat Mehmood; Saleem Ullah Shahid; Shahida Hasnain
Journal:  Ital J Pediatr       Date:  2022-07-23       Impact factor: 3.288

9.  Correlations between ISL1 rs1017 polymorphism and congenital heart disease risk: A PRISMA-compliant meta-analysis.

Authors:  Zhaohong Ding; Wenke Yang; Kang Yi; Yunhan Ding; Dan Zhou; Xiaodong Xie; Tao You
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.